Please assess the completion status of the following clinical trial:

Trial Title: THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (age 18 or older)~2. Documented SCD~3. New or pre-existing CVC planned for long term use (at least 6 months)~4. Able to provide written consent~Exclusion Criteria:~1. Contra-indication to prophylactic dose anticoagulation or active bleeding at discretion of treating physician~2. Already on anticoagulation (prophylactic or therapeutic dose) for an indication other than CVC thromboprophylaxis~3. Previous VTE within the past 3 months~4. Pregnant, within 6 weeks post-partum, or active breast feeding~5. Creatinine clearance \<30mL/min (as calculated by Cockcroft-Gault equation\[67\])~6. Acute hepatitis or chronic active hepatitis~7. Cirrhosis with Child-Pugh score B or C~8. Platelet count \< 50 x109/L~9. Weight \<40kg~10. Uncontrolled HTN (systolic blood pressure \> 170mmhg, or diastolic blood pressure\> 100mmhg) despite antihypertensive treatment~11. On palliative care~12. On dual antiplatelet therapy, or high dose single agent aspirin \> 325mg/day~13. On combined P-glycoprotein and strong cytochrome P450 3A4 inhibitors (including but not limited to ketoconazole and protease inhibitors)~14. On combined P-glycoprotein and strong cytochrome P450 3A4 inducers (including but not limited to rifampin, phenytoin, phenobarbital, carbamazepine, and st. john's wort)~15. Active cancer or treatment for cancer excluding basal cell carcinoma~16. Known allergy to study drug~17. Strong indication for thromboprophylaxis at discretion of treating physician~18. Significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban thromboprophylaxis (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).